The Role of Contrast-Enhanced Imaging Methods in Breast Cancer Early Diagnostics and Treatment Planning

Оn March 27, 2023, а multidisciplinary Advisory Board meeting was held in Moscow with the participation of Е.V. Artamonova, Е.А. Busko, V.V. Didenko, А.D. Zikiryakhodzhaev, М.S. Karpova, G.Е. Kvetenadze, P.V. Krivorot’ko, М.L. Mazo, А.V. Petrovsky, О.S. Puchkova, S.V. Serebryakova under the chairmanship of I.Е. Tyurin and N.I. Rozhkova. The participants discussed different issues of early diagnostics and treatment planning of breast cancer. We present the conclusion made by the Advisory Board.

1. Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022; 95(1130): 20211033. https://doi.org/10.1259/bjr.20211033.

2. Kaprin AD, Starinskiy VV, Shakhzadova AO (Eds). Malignant neoplasms in Russia in 2022. Мoscow: Herzen Moscow Scientific Research Oncological Institute – branch of National Medical Research Center for Radiology; 2023: 252 pp (in Russ).]

3. Understanding breast changes and conditions: a health guide. Available at: https://www.cancer.gov/types/breast/breastchanges/understanding-breast-changes.pdf (accessed March 31, 2024).

4. Jochelson MS, Lobbes MBI. Contrast-enhanced mammography: state of the art. Radiology. 2021; 299(1): 36–48. https://doi.org/10.1148/radiol.2021201948.

5. Mann RM, Cho N, Moy L. Breast MRI: state of the art. Radiology. 2019; 292(3): 520–36. https://doi.org/10.1148/radiol.2019182947.

6. Veenhuizen SGA, de Lange SV, Bakker MF, et al. Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. Radiology. 2021; 299(2): 278–86. https://doi.org/10.1148/radiol.2021203633.

7. Kaprin AD, Rozhkova NI (Eds). National guideline. Mammology. Мoscow: GEOTAR-Media; 2021: 372 pp (in Russ).]

8. Kaprin AD, Rozhkova NI (Eds). Medical logistics of breast cancer detection. Мoscow: GEOTAR-Media; 2024: 345 pp (in Russ).]

9. Mainiero MB, Lourenco A, Mahoney MC, et al. ACR appropriateness criteria breast cancer screening. J Am Coll Radiol. 2016; 13(11S): R45–9. https://doi.org/10.1016/j.jacr.2016.09.021.

10. NCCN guidelines version 3. Breast cancer screening and diagnosis. 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf (accessed March 26, 2024).

11. Fallenberg EM, Dromain C, Diekmann F, et al. Contrastenhanced spectral mammography: Does mammography provide additional clinical benefits, or can some radiation exposure be avoided? Breast Cancer Res Treat. 2014; 146(2): 371–81. https://doi.org/10.1007/s10549-014-3023-6.

12. Diekmann F, Diekmann S, Taupitz M, et al. Use of iodine-based contrast media in digital full-field mammography – initial experience. Rofo. 2003; 175(3): 342–5. https://doi.org/10.1055/s-2003-37828.

13. Diekmann F, Diekmann S, Jeunehomme F, et al. Digital mammography using iodine-based contrast media: initial clinical experience with dynamic contrast medium enhancement. Invest Radiol. 2005; 40(7): 397–404. https://doi.org/10.1097/01.rli.0000167421.83203.4e.

14. Weinstein SP, Slanetz PJ, Lewin AA, et al. ACR Appropriateness Criteria® supplemental breast cancer screening based on breast density. J Am Coll Radiol. 2021; 18(11S): S456–73. https://doi.org/10.1016/j.jacr.2021.09.002.

15. Kaprin AD, Rozhkova NI (Eds). The technological process of X-ray mammography. Мoscow: GEOTAR-Media; 2024: 138 pp (in Russ).]

16. Diekmann F, Bick U. Tomosynthesis and contrast-enhanced digital mammography: recent advances in digital mammography. Eur Radiol. 2007; 17(12): 3086–92. https://doi.org/10.1007/s00330-007-0715-x.

17. Sardanelli F, Newstead GM, Putz B, et al. Gadobutrol-enhanced magnetic resonance imaging of the breast in the preoperative setting: results of 2 prospective international multicenter phase III studies. Invest Radiol. 2016; 51(7): 454–61. https://doi.org/10.1097/RLI.0000000000000254.

18. Endrikat J, Schmidt G, Haverstock D, et al. Sensitivity of contrastenhanced breast MRI vs X-ray mammography based on cancer histology, tumor grading, receptor status, and molecular subtype: a supplemental analysis of 2 large phase III studies. Breast Cancer. 2022; 16: 11782234221092155. https://doi.org/10.1177/11782234221092155.

19. ESUR guidelines on contrast agents 10.0. European Society of Urogenital Radiology. Available at: https://www.esur.org/esurguidelines-on-contrast-agents/ (accessed March 31, 2024).

20. ACR Manual on contrast media. 2023. Available at: https:// www.acr.org/-/media/ACR/files/clinical-resources/contrast_ media.pdf (accessed March 31, 2024).

21. van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury – Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2018; 28(7): 2845–55. https://doi.org/10.1007/s00330-017-5246-5.

22. Nijssen EC, Nelemans PJ, Rennenberg RJ, et al. Prophylactic intravenous hydration to protect renal function from intravascular iodinated contrast material (AMACING): long-term results of a prospective, randomised, controlled trial. EClinMed. 2018; 4–5: 109–16. https://doi.org/10.1016/j.eclinm.2018.10.007.

23. Nijssen EC, Nelemans PJ, Rennenberg RJ, et al. Prophylaxis in high-risk patients with eGFR < 30 mL/min/1.73 m2: get the balance right. Invest Radiol. 2019; 54(9): 580–8. https://doi.org/10.1097/RLI.0000000000000570.

24. Nijssen EC, Nelemans PJ, Rennenberg RJ, et al. Evaluation of safety guidelines on the use of iodinated contrast material: conundrum continued. Invest Radiol. 2018; 53(10): 616–22. https://doi.org/10.1097/RLI.0000000000000479.

25. NCCN guidelines version 1. BRCA-pathogenic/likely pathogenic variant – positive management. 2023. Available at: https://cliniclancette.ru/docs/genetics_bop-2023.pdf (accessed March 31, 2024).

26. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. 2024. Available at: https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2823%2905104-9 (accessed March 31, 2024).

27. American Cancer Society recommendations for the early detection of breast cancer. Available at: https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-earlydetection-of-breast-cancer.html (accessed March 31, 2024).

28. Ministry of Health of the Russian Federation. Methodological recommendations for the implementation of the population screening program for breast malignancies among the female population. Available at: http://onkokms.ru/images/doc/vracham/popsk.pdf (in Russ) (accessed March 31, 2024).]

29. Association of Oncologists of Russia, Russian Society of Clinical Oncology, Russian Society of Oncomammologists. Clinical guidelines. Breast cancer. 2021. Ministry of Health of the Russian Federation. Available at: https://cr.minzdrav.gov.ru/schema/379_4 (in Russian) (accessed 31.03.2024).]

30. Sardanelli F, Trimboli RM, Houssami N, et al. Magnetic resonance imaging before breast cancer surgery: results of an observational multicenter international prospective analysis (MIPA). Eur Radiol. 2022; 32(3): 1611–23. https://doi.org/10.1007/s00330-021-08240-x.

31. NCCN guidelines version 2. Breast cancer. 2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed March 26, 2024).

32. Ali-Mucheru M, Pockaj B, Patel B, et al. Contrast-enhanced digital mammography in the surgical management of breast cancer. Ann Surg Oncol. 2016; 23(Suppl 5): 649–55. https://doi.org/10.1245/s10434-016-5567-7.

33. Barra FR, Sobrinho AB, Barra RR, et al. Contrast-enhanced mammography (CEM) for detecting residual disease after neoadjuvant chemotherapy: a comparison with breast magnetic resonance imaging (MRI). Biomed Res Int. 2018; 2018: 8531916. https://doi.org/10.1155/2018/8531916.